Daily Archives: December 17, 2021

Depression is a mental condition characterized by consistent feelings of sadness and low mood. Its normal to feel down or sad from time to time. Lifes demands can be overwhelming sometimes and put people in a state of emptiness or hopelessness. If these feelings remain for longer than usual, the individual may be battling depression.

The feelings of sadness and low mood from depression range from mild to severe, and it isnt something people can snap out of by simply getting their acts together. It can affect every aspect of a persons life, including work, play, and study. Depression is the worlds most common mental health condition and can get worse if not properly treated. Its also the leading cause of disability worldwide and affects members of all age groups. A 2019 study showed that 18.5 percent of US adults have depression in any given two-week period.

Untreated depression can get severe and worsen the symptoms of other conditions like diabetes, cancer, and asthma. Theres no cure for depression, but a person can effectively manage the condition with drug treatment, psychotherapy, and natural remedies.

Its difficult to point to a single reason for depression. Having depression is more often than not the result of an interplay of biological or circumstantial factors. The most common possible causes of depression include:

An imbalance of brain chemicals that regulate mood and behavior can trigger depressive episodes. Individuals with a less active frontal lobe also seem to report more cases of depression than the rest of the population.

A family history of depression can increase an individuals risk of developing the condition and related mood disorders.

Some medical ailments like heart attack, stroke, insomnia, cancer, and Parkinsons disease may increase depression risk. Those who experience accidents, physical or emotional pain for prolonged periods are also more likely to develop depression.

Changes in estrogen and progesterone levels during menstruation, postpartum period, perimenopause, and menopause can trigger depression.

Witnessing or experiencing abuse, trauma, and other violent events, especially during childhood, can affect how a person responds to fear and stress, thus increasing their likelihood of developing depression later in life.

Indiscriminate drug or alcohol use can lead to cases of depression.

The symptoms of depression vary in type and severity among individuals. A temporary feeling of sadness or low mood may not be depression. For a definite diagnosis, a patient must experience some of these symptoms daily for at least two weeks:

Depression treatment involves drugs that attempt to restore the balance of brain chemicals. The most commonly prescribed medications for depression are:

SSRIs act by increasing the amount of serotonin in the brain. Theyre the most prescribed drugs in depression treatment. SSRI examples include Zoloft, Paxil, and Lexapro.

SNRIs raise the levels of serotonin and norepinephrine in the brain. Common examples include Effexor XR, Pristiq, and Cymbalta.

TCAs also increase brain serotonin and norepinephrine levels. They may present more side effects than SSRIs and SNRIs, so they must be used cautiously. Elavil, Tofranil, and Sinequan are some of the commonly used brands.

MAOIs increase the levels of serotonin, norepinephrine, dopamine, and tyramine in the brain. Their side effects limit their use, and theyre only prescribed if a patient isnt responding to other classes of antidepressants. They include Nardil, Marplan, and Emsam.

Patients who dont respond positively to drug treatment can explore alternative therapies and lifestyle modifications as a substitute or adjunct to medication.

Some of these treatments are unapproved by regulatory authorities even though they may have some scientific backing. Its essential to speak to a professional before opting for these types of depression treatment.

Traditional Chinese healing systems find use in a significant number of conditions. Acupuncture is a type of treatment in which fine needles are inserted into specific points in the body to relieve symptoms.

The idea behind acupuncture is that disease is the result of an imbalance in energy. This treatment seeks to restore the balance of that energy. Studies show that acupuncture may help patients respond better to medications.

Traumatic circumstances can trigger depressive episodes, and patients can prevent those occurrences by changing how they respond to such conditions. Meditative practices like yoga and mindfulness help take the mind away from circumstances that can trigger depression or cause a relapse.

Some supplements like 5-hydroxytryptophan (5-HT), Omega-3-fatty acids, and S-adenosylmethionine (SAMe) may affect brain chemicals in ways that improve mood and reduce symptoms of depression. The FDA doesnt regulate these supplements, so patients must speak with their healthcare provider before using them.

Some herbs and plants have found use in depression treatment. Like other natural treatments, manufacturers may exaggerate the effectiveness of these herbs, so its up to the patient to work with their doctors to find out whether these herbs may help their symptoms. Common herbs for depression treatment include ginseng, St. Johns wort, chamomile, and lavender.

Generally, improving ones way of living can significantly ease depression symptoms or prevent a relapse. Simple activities like eating right, engaging in regular exercises, and developing a sleep routine can help depression. Other changes can include avoiding stress, doing what one loves, and finding time to relax with friends and family.

Depression is a common mental condition affecting lots of people and causing significant loss of productivity. Thankfully, it can be managed and even reversed with the right combination of medicine, alternative therapies, and lifestyle changes.

The manifestations of depression vary among patients. Patients should work with their healthcare provider to devise a treatment combination that offers them the best possible outcome during treatment.

Read the rest here:

How to Battle Depression With Alternative Therapies - South Florida Caribbean News

Flashing lights or zigzag lines appear in your field of vision. Perhaps you lose your peripheral vision or are not able to see at all. Your limbs may feel weak or like they dont belong to you. Speech may be slowed or impossible.

These symptoms are often followed by a feeling of nausea, sensitivity to light and sound, and finally an intense headache on one or both sides of the head.

You may be having a migraine headache, which may then cause you to wonder: Why do some people get these painful episodes, while others do not? What distinguishes migraines from more typical headaches? And lastly, what can you do to treat them?

More than 37 million people in the United States, and about 1 billion people worldwide, suffer from migraine headaches, according to the American Migraine Foundation (AMF). At least one person in an estimated one out of every four households is impacted by the disorder, and one in eleven children experience migraines.

According to research published in Headache: Journal of Head and Face Pain, almost 15 percent of the population worldwide experiences some form of migraines. Even more people may be affected, as it is under-diagnosed.

In Taos County, with a population of 32,771 (U.S. Census 2021) that means there are close to 5,000 people here who suffer from migraines.

Migraine is an inherited neurological disorder that is characterized by over excitability of specific areas of the brain, according to the AMF website.

Although it is not fully understood what happens in the brain to bring on a migraine, people who are affected are more likely to be influenced by certain factors, called triggers. These can include bright lights, changes in the weather, allergies, smells, hormonal fluctuations, some foods, alcohol, caffeine, stress and sleep problems. Through tracking foods and other factors, some people are able to discover their triggers and work to reduce or eliminate them.

About one out of every three migraine sufferers experiences visual disturbances, including flashing lights, zigzag lines, or temporary loss of vision. A headache, nausea, vomiting, and extreme sensitivity to light and sound can follow (National Institute of Neurological Disorders and Stroke). Some who experience migraines become increasingly sensitive to triggers and may develop a pattern of chronic or even daily migraines.

What can you do about them?

Jamie Sampere, family nurse practitioner at Taos Whole Health Integrative Care, says that when people come to the practice with migraines, the first step involves looking at methods that avert the headaches at their onset. The triptan family of drugs is the first line of defense, explains Sampere.

These drugs, which include the medications sumatriptan and zolmitriptan, block pain pathways in the brain. If these medications arent enough to address the problem, she suggests that the patient see a neurologist to look more closely at the type of headache and potential causes. There are a lot of clinical trials because the condition is so common, Sampere says. There are injectable approaches including Botox that works because it helps relax the muscles near the jaw and diffuse tension that can trigger a migraine. Other drugs that may be used preventively include antidepressants, like amitriptyline.

In addition to medication, Sampere suggests looking at lifestyle to identify possible triggers, such as coffee, gluten, levels of activity and stress, time spent on electronics and family issues.

Consider lifestyle changes such as reducing stress and improving levels of activity to see if that can help alleviate symptoms, she recommends.

As Sampere notes, treatments that have been developed for other uses are also being used to address migraines. However, for the first time, a migraine-specific medication was approved by the Food and Drug Administration (FDA) in 2018. Called Aimovig, this preventative treatment for adults with migraines is given by monthly self-injection. Aimovig is the first medication to be approved by the FDA from a new class of drug that works by blocking the activity of a peptide (a short chain of amino acids), which is involved in migraine attacks. Research has shown that the medication reduces the number of migraine days for many patients, according to the FDA.

To find relief from migraines, people also sometimes look to alternative therapies that can replace or be used in conjunction with medication and lifestyle changes. Although there are fewer clinical trials involving these types of therapies, some patients have found them to be effective.

Rob Hawley, co-founder of Taos Herb, explains that treating migraines is complicated. The causes are manifold, including hormones, food, chemical additives, stress, traumatic neck and head injuries, and vascular irregularities in the blood vessels," he said. "There is no single answer in complementary medicine to address all these different kinds of migraines, but there are a number of things worth trying.

Hawley emphasizes that it is important to work with your physician if you have migraines as they may be a symptom of an underlying condition. Additional causes to consider are food allergens, as well as airborne allergens, such as pollen and pet dander, among others. These can cause inflammation in the body, which can exacerbate many conditions. Looking at anti-inflammatory diets and adding healthy fats, like omega-3s, can reduce inflammation and lead to overall better health. Moderate exercise is also helpful but excessive activity can lead to an increase in inflammation. Reducing stress alone can lessen migraines.

Because tension in the neck can trigger a migraine in someone who is predisposed to get them, Hawley suggests stretching and massaging the neck and applying heat. Muscular tension can worsen if a person is dehydrated or has an imbalance in electrolytes, so drinking plenty of water is important.

Avoiding possible triggers, such as fermented food, wine, food additives and nuts like cashews may be worth exploring as well. Hawley explains that, along with complementary medicine, avoiding these triggers is a critical part of avoiding migraines. Certain lifestyle changes, like eating whole foods rather than sugary or processed foods, can make a big difference.

Hawley adds that increasing magnesium levels through supplements can help relax the muscles and reduce migraines.

Essential oils, such as lavender and sweet birch, when applied to the temples and back of the neck, can help soothe migraines as well, he said. But Hawley emphasizes that essential oils should be used in small quantities and kept out of the eyes.

Hawley also says that feverfew has aspirin-like qualities. Feverfew, in combination with butterbur, can be found in supplements like MigraEze at Taos Herb. With the availability of CBD oil, more people are using liquid preparations like Kinetic Gate CBD drops made in Taos and available at Cids and Taos Herb to treat migraines as they begin. Hawley points out that while CBD may have broad medicinal applications, there are not yet many studies that allow us to understand all of its components and its effectiveness. CDB does seem to reduce inflammation and pain in some people, says Hawley.

Acupuncture can also be used to regulate migraines, says Dr. Keith Christian, DOM at Taos Chiropractic. Acupuncture involves the insertion of fine needles into specific points in the body. These points have been mapped by Chinese practitioners over the past 2,000 years, according to the American Society of Acupuncturists. The effectiveness of acupuncture in treating migraines is supported by research reported by the National Center for Biotechnology Information in 2020.

Techniques like biofeedback, which involves monitoring body functions and learning to relax under stress, has shown promise in reducing the incidence of migraine headaches with 62 percent of patients in one study showing either a major or total improvement in the incidence of migraine. The researchers found that this method worked better than medication in reducing migraines, according to a 2010 study in Behavioral and Brain Functions Journal.

In the award-winning 2017 documentary film Out of my Head, health practitioners explore various healing approaches and recommend techniques like reflexology (which involves the application of pressure to the feet or hands), stress management, mindfulness and meditation and yoga as ways to help calm and regulate the nervous system.

The documentary reports that there are 113 million lost workdays per year in the US that results in a loss to the economy of $13 billion annually. Students sometimes have to miss school because of migraines. Anxiety and depression can also occur alongside migraines or serve as triggers.

Migraines are estimated to be the third most common disease in the world by the Migraine Research Foundation. But, with new medications, as well as lifestyle changes and alternative therapies, there is hope that migraines can be managed in such a way that those who suffer from them can lead healthier and happier lives.

Visit link:

Migraine headaches: What causes them and how to treat them - taosnews

A woman holds a handful of marijuana flower buds in Vancouver. Photo: Don MacKinnon / AFP

The first country in Southeast Asia to legalize marijuana for medical use and research in 2018, Thailand is set to loosen its laws around cannabis further as it advances towards full legalizationwith plans to remove the plants flowers and buds from its banned narcotics list announced last week.

What we have achieved so far is to declare that cannabis stems, roots, leaves and sprigs are not drugs, said public health minister Anutin Charnvirakul, also the deputy prime minister of Thailand, speaking at an agricultural event aimed to promote the cultivation of cannabis.

Starting next year, we will remove everythingstems, roots, sprigs, leaves, buds, flowers and seedsfrom the narcotics list.

A cannabis flower in Kingston, Jamaica. Photo: Angela Weiss / AFP

The tycoon-turned-politician once said that legalizing cannabis would be a win-win for Thais. The country became the first in Southeast Asia to legalise the drug for medical use and research in 2018. On this most recent legalization of the use and sale of cannabis flowers and buds, he said that it was an initiative that would help those hit hard by the pandemic.

When the economy is picking up and we dont have new products as alternatives, people will keep doing the same things and competing with one another, he said.

But if we offer them a choice, they can learn to build on it, creating new products and business models, which will in turn speed up the economic recovery.

Its new narcotics code, which officially came into effect on Dec. 9, no longer lists cannabis and hemp. And as early as next year, cannabis flowers and buds will be legal to use, process and sell outside of medical and research settings. Its a move that, according to Bangkok-based cannabis entrepreneur and legalization advocate Kitty Chopaka, was a savvy economic decision that was long overdue.

If we are going to fully legalize all parts of the cannabis plant for commercial purposes next year, it will still be with a lot of caveats, Kitty, founder and CEO ofElevated Estate, told VICE World News, adding that the move was only a small first step.

The ministries are testing the water first, but they do realize that if they dont allow for full access, Thais will know other ways to go about finding it.

Unlike stems, roots and leaves, cannabis flowers are typically rich in THC and are considered by scientists and experts to be the most potent part of the plant. This makes them highly sought-after as they can be consumed in numerous ways, including smoked in pipes and vaporizers, or rolled as joints and incorporated into edibles.

Because [previously] only medical marijuana had been legalized, Thai government officials sought to prevent people misusing parts of the plant to get high, Kitty explained.

Cannabis cultivation is currently strictly controlled in Thailand. Under an agreement facilitated by hospitals, universities and government officials, cannabis flowers and buds are removed at harvest. They are then either given to local hospitals to be made into alternative medicine, sent to medical units and facilities at local universities across the country for research, or disposed of completely.

In a region with some of the harshest drug laws globally, cannabis entrepreneurs and vendors in Thailand have cashed in on loosened laws since 2018, with a boom in cannabis-based products. With the new law enabling licensed growers of cannabis to use the entire plant for medicinal and commercial purposes, that boom is set to grow as producers can create products like edibles, oils, cosmetics and even K-Y Jelly lubricant.

The developments mean that the cannabis industry in Thailand is growing and will only get bigger, Kitty said. We could probably see a cannabis and hemp-related Thai company that might go into the stock market and big companies slowly making their way into Thailand as we become an actual market.

The entrepreneur also warned of competition should Thailands neighbors catch a whiff of the potentially lucrative trade.

Everything else should slowly follow, and if Thailand does well and others in the region like Malaysia, Laos and Cambodia see this, what makes us think that they wont jump on board?

Follow Heather Chen on Twitter.

Continue reading here:

Cannabis Buds and Flowers Will Soon Be Legalized in Thailand. Heres What That Means. - VICE

Diana Mazionyte was diagnosed with liver and colon cancer earlier this year after experiencing stomach pain.

The mum-of-two and her family were completely shocked as Diana has been healthy throughout her life.

"I was shocked, I cried," said Diana. "I rang home and told my husband, and he said it has to be a mistake, you're healthy."

The cancer she has is very rare and at stage four.

Diana wants to be present in her children's lives, and she is seeking alternative options to chemotherapy.

"I made the decision in my head, I'm going with alternative medicine," said Diana. "I didn't want to be at home sick for six months minimum after chemo, maybe longer after radiation or surgery. I don't want that life.

"I have two young kids, I don't want to be like bag of stones on their shoulder or a patient in the house."

This decision worried her children, but they did come around to the idea.

Diana has sought Oxygen/Ozone therapies, Infra-Red sauna therapy, intravenous vitamin C treatments, mistletoe therapy, herbal treatments as well as healthier diet choices and supplements. She has been on a juice diet to help her stomach, but she has been able to gradually move back to solid foods.

Diana has already begun weekly various Ozone therapies which are very expensive. She is also in the process of receiving vitamin C injections soon, which could greatly benefit her.

"I'm feeling much better already," said Diana. "I'm getting psychotherapist sessions, which helps me a lot."

She is so thankful for the donations she has received so far which have helped her so far with her treatment, however she is now looking into experimental treatments abroad.

These types of treatment are available Germany and Mexico, but they are also very costly.

"These clinics provide some of the best cancer treatments in the world," said Diana.

You can check out Diana's fundraiser here.

Read more here:

Galway mum suffering with liver and colon cancer appeals for help to seek treatment abroad - RSVP Live

PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ --Inovio(NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety data in participants from REVEAL1, completing enrollment in REVEAL2, and advancing its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN. In addition, INOVIO's development partner within Greater China (mainland China, Hong Kong, Macao, Taiwan), ApolloBio Corp. ("ApolloBio"), dosed the first participant in a separate Phase 3 trial in China.

Key Updates for VGX-3100:

- REVEAL2 INOVIO's second global Phase 3 clinical trial of VGX-3100 for cervical HSIL is fully enrolled and top-line efficacy and safety data are expected to be available in 2H22.- REVEAL1 INOVIO completed the 52-week safety follow-up of participants in REVEAL1, INOVIO's first global Phase 3 trial of VGX-3100, and the safety profile of VGX-3100 observed at Week 36 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88.- Pre-treatment Biomarker INOVIO and QIAGEN have made progress in biomarker development by identifying candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature in a pre-treatment in vitro diagnostic to improve the primary clinical outcome for biomarker-positive patients with cervical HSIL.- Phase 3 Trial in China The first participant has been dosed in the Phase 3 trial of VGX-3100 for cervical HSIL in China. This trial is being run by ApolloBio and is similar in design to REVEAL2. The trial is expected to enroll up to 84 participants.

Dr. J. Joseph Kim, President and CEO of INOVIO, said, "We are making strong progress in developing INOVIO's immunotherapies treating HPV-associated cervical HSIL. Left untreated, cervical HSIL may progress to cancer. VGX-3100 has the potential to be the first approved immunotherapy and non-surgical alternative for women with cervical HSIL and we look forward to advancing our efforts from our Phase 3 studies through commercialization."

Dr. Jeffrey Skolnik, Senior Vice President of Clinical Development and Program Lead for VGX-3100, added, "Completing enrollment for REVEAL2, and reporting on our long-term data from REVEAL1, are important milestones for VGX-3100 and an opportunity to advance women's health, given the lack of a non-surgical therapeutic for cervical HSIL. With our two Phase 3 studies now fully enrolled, INOVIO remains on target for the topline efficacy readout from this study in the second half of 2022."

INOVIO's Phase 3 program in cervical HSIL is assessing the efficacy of VGX-3100 to regress cervical HSIL, a direct precursor to cervical cancer, and to eliminate the HPV-16 and/or HPV-18 infection that causes these lesions. The REVEAL studies are prospective, randomized, double-blind, placebo-controlled trials evaluating adult women with HPV-16 and/or HPV-18 positive biopsy-proven cervical HSIL. REVEAL1 provided one-year post-endpoint safety data for a minimum of 198 participants randomized, while REVEAL2 will provide efficacy and one-month safety data for a minimum of 198 participants. For more information on the REVEAL1 and REVEAL2 studies, please visit clinicaltrials.gov (search identifier NCT03185013 and NCT03721978, respectively).

INOVIO completed the 52-week safety follow-up of participants in REVEAL1 and showed that the safety profile of VGX-3100 at Week 36 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88. There was no substantial change in the per-protocol assessment of primary efficacy from the mITT analysis that was previously reported for REVEAL1 (link).

Additionally, INOVIO is advancing its partnership with QIAGEN to co-develop a liquid biopsy-based diagnostic product based on next-generation sequencing (NGS) technology to guide clinical decision-making for the use of VGX-3100 in cervical HSIL. This biomarker, if validated, has the potential to increase the probability of clinical response in biomarker-positive women with cervical HSIL. QIAGEN offers an extensive expertise in technologies from polymerase chain reaction (PCR) to NGS for diagnostic development. INOVIO anticipates having additional information on its biomarker development in 2022.

Separately, INOVIO's partner ApolloBio dosed the first participant in the Phase 3 clinical trial of VGX-3100 in China. The Phase 3 trial in China is similar in design to REVEAL1 and REVEAL2 randomized, double-blinded, placebo-controlled. The trial is expected to enroll 84 participants. In 2018, the companies signed an agreement providing ApolloBio with the exclusive right to develop, manufacture and commercialize VGX-3100 within Greater China (link).

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO has clinically shown that a DNA vaccine candidate can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2/3 clinical trial; the Phase 3 segment of which has received regulatory approvals to proceed in Colombia, Mexico, Brazil, Philippines, India, Thailand, and the United States. INOVIO's partners, Advaccine Biopharmaceuticals and International Vaccine Institute, are also evaluating INO-4800 in ongoing clinical trials in China and South Korea, respectively.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit http://www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.comInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

View original content:https://www.prnewswire.com/news-releases/inovio-highlights-key-updates-on-phase-3-program-for-vgx-3100-its-dna-based-immunotherapy-for-the-treatment-of-cervical-hsil-caused-by-hpv-16-andor-hpv-18-301443997.html

SOURCE INOVIO Pharmaceuticals, Inc.

Originally posted here:

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or...